COX inhibitors

COX (Cyclooxygenase), which is also called prostaglandin-endoperoxide synthase, plays the rate-limiting role in the process of converting arachidonic acid to prostaglandins and thromboxane. Cyclooxygenase is the molecular target for aspirin and NSAIDs(non-steroidal antiinflammatory drugs). COX contains 3 isoenzymes which are called COX-1, COX2, and COX3.

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S1396 Resveratrol (trans-Resveratrol) Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases(LOX, IC50=2.7 μM), kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
Aging Cell, 2025, e70075
Biomed Pharmacother, 2025, 190:118393
Breast Cancer Res, 2025, 27(1):186
Verified customer review of Resveratrol (trans-Resveratrol)
S1261 Celecoxib (SC-58635) Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Cancer Cell, 2025, S1535-6108(25)00494-5
Emerg Microbes Infect, 2025, 14(1):2522877
Breast Cancer Res, 2025, 27(1):186
Verified customer review of Celecoxib (SC-58635)
S3017 Aspirin Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. This compound induces autophagy and stimulates mitophagy.
J Biol Chem, 2025, 301(2):108195
PLoS One, 2025, 20(9):e0332825
iScience, 2024, 27(10):110862
S1723 Indomethacin Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Nature, 2024, 10.1038/s41586-024-08257-4
Cell Rep Med, 2024, 5(12):101849
Int J Mol Sci, 2024, 25(18)10162
Verified customer review of Indomethacin
S8433 NS-398 (NS398) NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide) is a selective inhibitor of cyclooxygenase-2 (COX-2), with IC50 values for human recombinant COX-1 and -2 of 75 and 1.77 μM, respectively.
Antioxidants (Basel), 2025, 14(8)945
Elife, 2023, 12e82970
PLoS Negl Trop Dis, 2022, 16(4):e0010402
Verified customer review of NS-398 (NS398)
S2007 Sulindac Sulindac(MK-231) is a non-steroidal COX inhibitor, which potently inhibits prostaglandin synthesis, used in the treatment of acute or chronic inflammatory conditions.
Nanoscale, 2025, 17(16):9947-9962
iScience, 2024, 27(10):110862
Nat Commun, 2023, 14(1):5351
Verified customer review of Sulindac
S4686 Vitamin E Vitamin E (D-alpha-Tocopherol) is a fat-soluble vitamin with potent antioxidant properties. It is a potent peroxyl radical scavenger and inhibits noncompetitively cyclooxygenase activity in many tissues, also inhibits angiogenesis and tumor dormancy through suppressing vascular endothelial growth factor (VEGF) gene transcription.
Elife, 2025, 13RP94169
Cancer Drug Resist, 2025, 8:45
Signal Transduct Target Ther, 2024, 9(1):109
S2410 Paeoniflorin (NSC 178886) Paeoniflorin (NSC 178886, Peoniflorin), a herbal constituent extracted from the root of Paeonia albiflora Pall, reduces COX-2 expression. It alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.
World J Emerg Med, 2024, 15(3):206-213
Kaohsiung J Med Sci, 2023, 10.1002/kjm2.12736
J Pers Med, 2022, 12(2)258
S2903 Lumiracoxib Lumiracoxib (COX-189) is a novel, selective COX-2 inhibitor with Ki of 0.06 μM. This compound also inhibits COX1 with Ki of 3 μM.
Int J Biol Macromol, 2021, 187:603-613
Cells, 2020, 9(9)E2005
J Am Heart Assoc, 2020, 9(1):e013470
Verified customer review of Lumiracoxib
S7889 Xanthohumol Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. This compound inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. It is also a potent antiviral agent against a series of DNA and RNA viruses. This chemical induces growth inhibition and apoptosis in cancer cells. Phase 1.
Oncotarget, 2025, 16:532-544
J Cell Sci, 2024, 137(20)jcs262162
Antiviral Res, 2022, 207:105416

Signaling Pathway Map